Literature DB >> 5213

Suppression of experimental allergic encephalomyelitis in guinea-pigs with poly-L-lysine.

E Chelmicka-Szorc, B G Arnason.   

Abstract

Poly-L-lysin (PLL) given subcutaneously in a dose of 3 mg/day suppresses experimental allergic encephalomyelitis in guinea-pigs. The suppressive effect of PLL can still be demonstrated when administration is begun 8 days post-immunization. The effect is disease- and species-specific since PLL (3 mg/day) does not suppress experimental allergic orchitis in guinea-pigs, nor does it suppress EAE in rats (1-5 mg/day). PLL (0-2 mg/day) does not decrease the severity of graft-versus-host disease (GVH) in mice as judged by the spleen/body weight assay.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 5213      PMCID: PMC1538429     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  LARGE DOSE CORTICOSTEROID THERAPY OF EXPERIMENTAL AND HUMAN DEMYELINATING DISEASES.

Authors:  R F KIBLER
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Graft versus host reactions. Their natural history, and applicability as tools of research.

Authors:  M SIMONSEN
Journal:  Prog Allergy       Date:  1962

3.  Encephalitogenic activity of poly-L-lysine.

Authors:  S E KORNGUTH; D R BENNETT; H G THOMPSON; G M ZURHEIN; M A STAHMANN
Journal:  Nature       Date:  1962-03-17       Impact factor: 49.962

4.  Successful treatment of experimental allergic encephalomyelitis (EAE) in guinea pigs with homologous myelin basic protein.

Authors:  B F Driscoll; M W Kies; E C Alvord
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

5.  In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis.

Authors:  C Webb; D Teitelbaum; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1973-05       Impact factor: 5.532

6.  Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen.

Authors:  D Teitelbaum; C Webb; A Meshorer; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1973-05       Impact factor: 5.532

7.  Prevention of experimental allergic encephalomyelitis by nonencephalitogenic basic peptides.

Authors:  G A Hashim; F J Schilling
Journal:  Arch Biochem Biophys       Date:  1973-05       Impact factor: 4.013

8.  Experimental allergic aspermatogenic orchitis. 1. Isolation of a spermatozoal protein (AP1) which induces allergic aspermatogenic orchitis.

Authors:  J J Jackson; A Hagopian; D J Carlo; G A Limjuco; E H Eylar
Journal:  J Biol Chem       Date:  1975-08-10       Impact factor: 5.157

9.  The use of specific "lymphocyte" antisera to inhibit hypersensitive reactions of the "delayed" type.

Authors:  B H WAKSMAN; S ARBOUYS; B G ARNASON
Journal:  J Exp Med       Date:  1961-12-01       Impact factor: 14.307

10.  Linkage of susceptibility to experimental allergic encephalomyelitis to the major histocompatibility locus in the rat.

Authors:  R M Williams; M J Moore
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

View more
  1 in total

1.  Observations on the effects of protease inhibitors on the suppression of experimental allergic encephalomyelitis.

Authors:  M E Smith; L A Amaducci
Journal:  Neurochem Res       Date:  1982-05       Impact factor: 3.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.